Benefits of Remote Ischaemic Preconditioning in Vascular Surgery  by Twine, C.P. et al.
REVIEWBeneﬁts of Remote Ischaemic Preconditioning in Vascular Surgery
C.P. Twine a,*, S. Ferguson b, J.R. Boyle b
a South East Wales Vascular Network, Royal Gwent Hospital, Newport, UK
b Addenbrooke’s Hospital, Cambridge, UK* Co
Newpo
E-ma
1078
Surgery
http:WHAT THIS PAPER ADDS
Remote ischaemic preconditioning (RIPC) is a physiological mechanism to protect against ischaemiaereperfu-
sion injury. Interest in the technique has exploded in recent years, with multiple randomised trials and meta-
analyses on the subject being published. This is the ﬁrst article to summarise the physiology, and critically
appraise the technique, trials and meta-analyses to date.Objectives: Remote ischaemic preconditioning (RIPC) is a physiological mechanism to protect against ischaemiae
reperfusion injury. It is a technique in which short pre-emptive periods of ischaemia and reperfusion are thought
to protect against ischaemiaereperfusion injury during procedures requiring longer periods of ischaemia.
Discovered in the 1980s, its clinical application has been investigated heavily since the ﬁrst human study in 2006.
The aim of this paper was to provide a review of this rapidly expanding subject.
Methods: This study consists of a narrative review of the literature focusing on previous meta-analyses and
randomised control trials.
Results: Five small randomised trials have been published on the effects of RIPC in vascular surgery. Several
randomised trials have been published in cardiac surgery and percutaneous coronary intervention. Meta-analysis
shows a signiﬁcant reduction in troponin levels and biomarkers of renal dysfunction in RIPC patients, but as yet
no convincing clinical beneﬁt. The largest powered randomised trial in cardiac surgery showed no beneﬁt to RIPC.
Conclusions: Current trials and therefore meta-analyses are generally underpowered. The technique is
physiologically sound but remains lacking in clear clinical beneﬁt.
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ReviewINTRODUCTION
Remote ischaemic preconditioning is one of the most
investigated topics in modern vascular medicine. Myriad
randomised trials have already been undertaken and 92 are
still registered or actively recruiting on ClinicalTrials.gov
(search date December 2013). The majority of these trials
were essentially pilot studies, reporting a variety of
different outcomes, and provided little evidence of actual
clinical beneﬁt. Meta-analyses would therefore be expected
to be of limited use, although a staggering 10 have been
published from these trials within the last 2 years.1e10
There is, however, sound scientiﬁc theory and the po-
tential of greater things to come from remote ischaemic
conditioning (RIPC) within this literature. The aim of this
topical review was to critically appraise and put the evi-
dence for this technique in a clinical context.rresponding author. C.P. Twine, Royal Gwent Hospital, Cardiff Road,
rt NP20 2UB, UK.
il address: chris_twine@hotmail.com (C.P. Twine).
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RIPC is a technique in which short pre-emptive periods of
ischaemia and reperfusion are thought to protect against
ischaemiaereperfusion injury during procedures requiring
longer periods of ischaemia. It is therefore of interest in
vascular surgery where the majority of procedures
require periods of ischaemia, and is relatively easy to
perform.
For example, during open abdominal aortic aneurysm
repair the common iliac could be clamped for 5 minutes
immediately after access to the peritoneal cavity. The
aortic dissection would proceed normally during this time
period. After this time the clamp is released, so a short
period of ischaemiaereperfusion has occurred. The same
effect may be achieved using a tourniquet on the thigh. A
degree of RIPC may happen when proximal control of
target vessels is achieved in open vascular surgery. This is
thought to “remotely” precondition every organ in the
body against ischaemiaereperfusion injury before the
longer periods of more extreme ischaemia the operation
will then require. This is then believed to limit the
dysfunction of other organs, such as the kidneys and
heart, caused by reperfusion.
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action
Ischaemic preconditioning is a physiological mechanism to
protect against ischaemiaereperfusion injury. It was
discovered in the 1980s by a team investigating adenine
triphosphate depletion (ATP) in myocytes.11 They were
investigating mechanisms of ATP depletion and lactic
acidosis leading to myocyte death. They initially presumed
that by exposing mammalian cardiac tissue to brief episodes
of ischaemia then reperfusion, they would deplete ATP and
lactate would accumulate at a constant rate. However,
instead they found that ATP actually depleted to a certain
critical level then stabilised during brief ischaemiaereper-
fusion cycles. At the same time, lactate production was
depressed. Observing this, they hypothesised that cell death
could be prevented by ischaemiaereperfusion cycles. They
were correct: cumulative cycles of ischaemiaereperfusion
allowed myocytes to survive far longer than the 40 minutes
seen in non-preconditioned myocytes. Preconditioning
preserved ATP levels, depressed lactate levels and delayed
cell death by a signiﬁcant period of time.12
The mechanism for this is still not fully understood.
Adenosine produced during the ﬁrst preconditioning cycle
appears to be the trigger for protection as rabbit hearts
exposed to adenosine show the same preconditioned effect
as with short cycles of ischaemia.13 Although the adenosine
signalling cascade from the sarcolemma has been studied in
detail, the resulting changes in ATP and lactate production
in the cell are still not understood.
From this point, research showed that when a different
organ, even skeletal muscle, was used for ischaemic pre-
conditioning it still conferred beneﬁt to myocytes.14 This was
termed remote ischaemic preconditioning (RIPC). It was then
a short step to human trials, as inducing skeletal muscle
ischaemia with a tourniquet is a relatively low risk procedure.
The ﬁrst human study was in children undergoing congenital
cardiac defect repair surgery.15 Thirty-seven patients were
randomised to RIPC or no RIPC.They found signiﬁcantly lower
levels of troponin (p¼ .04) and lower postoperative inotropic
requirements (p ¼ .03) in the RIPC group.15
By this time, interest in the technique was exploding, as
were pilot randomised trials. Trials were easy to perform,
low risk, and easy to power with relatively low patient
numbers. Although the initial trials examined cardiac
markers in cardiac surgery, this was soon extrapolated to
the cardiovascularly high-risk procedure open abdominal
aortic aneurysm (AAA) repair.16 Observations of changes in
renal function during that trial led to speciﬁc studies
examining renal injury.17 The same group then went on to
perform several trials examining the effects of RIPC in other
vascular surgical procedures, which are discussed in detail
below. Research also continued examining RIPC in percu-
taneous and open cardiac intervention.Evidence in AAA
Three randomised trials have examined the effects of
remote ischaemic preconditioning in elective open AAArepair,16e18 and one examined endovascular aneurysm
repair (EVAR).19 The open AAA studies performed limb RIPC
by iliac clamping, and the EVAR trial used a lower limb
tourniquet. These small, pilot studies were powered to
detect differences in myocardial injury,16,18,19 kidney
injury,17,19 and intestinal and pulmonary dysfunction
deﬁned predominantly by biomarkers.16 Three of the four
trials were performed at Addenbrooke’s Hospital in
Cambridge.16,17,19
Ali et al.16 examined the effect of RIPC on 82 patients
undergoing elective open AAA repair. They found a reduc-
tion in both troponin levels (p ¼ .005) and myocardial
infarction (MI) (p ¼ .006: deﬁned here by troponin and
electrocardiogram changes but without chest pain) in the
RIPC group. However, they powered the study for troponin
levels and do not discuss the clinical outcomes of the sig-
niﬁcant ﬁndings. They also found a reduction in renal
impairment (p ¼ .009) in the RIPC group. Renal impairment
was deﬁned here using creatinine levels (rising to
>177 mmol/L). There were, however, more (non-signiﬁcant)
suprarenal cross-clamps in the non RIPC group. Again, the
study was not powered to detect changes in creatinine.
Deﬁnitions of renal failure vary by study and therefore
introduce signiﬁcant heterogeneity into meta-analysis.
The group therefore followed up this trial by examining
the effect of RIPC on renal failure in open AAA,17 while at
the same time examining the cardiac and renal effects of
RIPC in EVAR.19 Powered to detect changes in postoperative
renal dysfunction after open AAA, the open AAA trial
randomised 40 patients and found that there was no dif-
ference after RIPC (p ¼ .07). This included both urinary
biomarkers and albuminecreatinine ratios. The EVAR trial
was again powered for renal dysfunction, but this time
found a signiﬁcant reduction in the urinary biomarker
retinol-binding protein (p ¼ .0001). There were, however,
no differences in creatinine levels or cardiac complications
in the 40 patients randomised.
The most recently published small RCT was from China.18
The authors examined intestinal and pulmonary dysfunction
(arterialealveolar oxygen tension ratio) after open AAA
repair in 62 patients. They found a signiﬁcant improvement
in pulmonary function in the RIPC group (p ¼ .039) and a
reduction in biomarkers (p < .001) and clinical grade
(p ¼ .014) of intestinal injury. Meta-analysis of these studies
is discussed below.Evidence in other vascular surgery
The Cambridge group also examined the effect of RIPC
during carotid endarterectomy.20 This pilot study examined
cerebral and cardiac protection via RIPC performed with a
thigh tourniquet, and randomised 70 patients. The trial was
powered to detect changes in saccadic latency (the time
taken to respond and ﬁx on a visual stimulus that appears
suddenly) rather than myocardial infarction. They found no
difference in stroke (no strokes during the trial, no differ-
ences in saccadic latency p ¼ .11) or cardiac outcomes
(p ¼ .97) during the trial.
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Meta-analysis of the four “pure” vascular trials published
before 201116,17,19,20 (1 trial has been published since18)
showed an improvement in myocardial infarction (deﬁned
predominantly by troponin changes) in the RIPC group but
no improvement in mortality, renal failure, or hospital stay,
as well as clinically relevant myocardial infarct (Table 1).4
The highest quality meta-analysis published on RIPC
included vascular and cardiac trials.2 This showed anTable 1. Meta-analyses including vascular studies of remote ischaemic
Author Year Trials included Number of studies
(participantsa)
Desai et al4 2011 Vascular and
endovascular
4 studies
(232 [115:117])
Brevoord2 2012 Vascular, endovascular,
open cardiac surgery,
percutaneous cardiac
intervention
23 studies
(1878 [954:924])
Li et al.5 2013 Vascular, endovascular,
open cardiac surgery,
percutaneous cardiac
intervention
10 studies
(924 [464:460])
Takagi and
Umemoto7
2011 Vascular and
open cardiac
9 studies
(488 unclear)
RCT ¼ randomised controlled trial; RIPC ¼ remote ischaemic precond
a Preconditionedenon-preconditioned.
b Deﬁned predominantly by troponin levels.improvement in biomarker-deﬁned myocardial infarction
but no difference in mortality, renal failure, major cardiac
events (including more clinically relevant deﬁnitions of
myocardial infarction), or length of stay.2 The ﬁnal two
meta-analyses in Table 1 were of lower quality and capture
fewer trials than the higher quality analyses.
Interestingly, the largest RCT examining AAA16 was a
signiﬁcant outlier in the cardiovascular event Forest plot of
the largest meta-analysis.2 This was the only trial with apreconditioning.
Type of
study
Major ﬁndings (OR, SMD,
and 95% CI)
Risk of bias
from included
studies
RCT RIPC improved:
Myocardial infarctionb:
(OR 0.31 [1.10e0.90] p ¼ .03)
No improvement:
Mortality: (OR 1.70 [0.91e5.92]
p ¼ .39)
Renal failure: (OR 0.74 [0.35e1.54]
p ¼ .42)
Hospital stay: (SMD 0.12
[2.38e2.13] p ¼ .91)
Low
RCT RIPC improved:
Myocardial infarctionb:
(OR 0.50 [0.31e0.82] p ¼ .005)
Peak troponin levels: (SMD 0.28
[0.47 e 0.09] p ¼ .003)
No improvement:
Mortality: (OR 1.22 [0.48e3.07]
p ¼ .68)
Renal failure: (SMD 1.88
[5.10e8.87] p > 0.05)
Major cardiac events:
(OR 0.65 [0.38e1.14] p ¼ .13)
Length of stay:
(SMD 0.04 [0.21e0.29} p > 0.05)
Moderate
RCT No improvement:
Mortality: (OR 1.21
[0.49e2.97] p ¼ .68)
Renal failure: (OR 0.73
[0.50e0.64] p ¼ .18)
Length of stay: (SMD 0.07
[0.50e0.64} p ¼ .81)
Moderate
RCT RIPC improved:
Peak troponin levels:
(SMD 0.74 [0.97 to 0.52]
p < .00001)
No improvement
Myocardial infarctionb:
(OR 0.02 [0.06e0.02] p ¼ .28)
Mortality: (OR 0.01
[0.03e0.05] p ¼ .65)
Moderate
itioning; SMD ¼ standardised mean difference.
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events. This study included 41 patients in each arm, and
was small compared to some trials of open cardiac surgery
which contained >100 patients in each arm. Myocardial
infarction was broadly deﬁned in this study by cardiac
troponin I (>0.40 ng/mL), and by the American College of
Cardiology/American Heart Association deﬁnition.16
The likely reason for the signiﬁcant ﬁndings in favour of
RIPC during open AAA therefore starts to look like type 1
error from underpowered trials. This is known to be a
problem when meta-analysing small randomised trials.21 An
example of this phenomenon is the signiﬁcant improvement
seen in postoperative troponin levels in the RIPC group
deﬁned as ‘myocardial infarction” in some trials (Table 1).
This translated into a non-signiﬁcant difference when this
result was examined as major adverse cardiac events, which
is far more clinically useful. Further evidence of the rela-
tively poor overall quality of these trials was the ﬁnding of a
moderate overall risk of bias in all of the largest meta-an-
alyses.22 It must be remembered that these were, by their
own admission, pilot studies.
However, the main question raised when trying to draw
meaningful conclusions from these analysis is: How relevant
is it to meta-analyse these trials together? They include a
clinically heterogeneous group of procedures which are not
directly comparable. Major adverse cardiac events are far
more common after open AAA and open cardiac surgery
than after percutaneous coronary intervention. Similarly, is
it relevant to include a study of carotid endarterectomy
with such trials? Performing meta-analysis in this manner
leads to high heterogeneity between studies, seen here
especially in major adverse cardiac events and troponin
release analyses.2,5,7 A lack of heterogeneity during meta-
analysis of small trials suggests that trials are simply un-
derpowered to detect differences for that outcome, the
best example in these meta-analyses being mortality rate
analyses.2,5,7
The results from these meta-analyses are therefore not
particularly useful and only really serve to proclaim that
which is obvious looking at the source data: further prop-
erly powered randomised trials are needed to test whether
RIPC is actually of any clinical use.
Interestingly, a recent large randomised trial of RIPC in
cardiac surgery has shown no beneﬁt. A total of 1,280 pa-
tients undergoing elective cardiac surgery were randomised
to RIPC (644 patients) or no RIPC (636 patients). The RIPC
was via an arm tourniquet. The trial showed no difference in
in-hospital mortality (p ¼ .392), cardiac (p ¼ .746), renal
(p ¼ .775), or stroke (p ¼ .978) complications.23 This may
be a reﬂection of what is to come when the properly
powered vascular trials report in the future.Future research
Other larger trials have been set up and are now recruiting.
For example, the SAVES study (Preconditioning Shields
Against Vascular Events in Surgery) is a large, multicentre
trial aiming to enrol 1,900 vascular patients to examinemajor adverse clinical events. The ERIPCCA study (Effect of
Remote Ischaemic Preconditioning on Clinical Outcomes in
CABG Surgery) is aiming to recruit 1,610 cardiac patients to
examine multiple effects, primarily major adverse cardiac
and cerebral events. These trials should answer the ques-
tion of whether RIPC improves clinical outcomes much
more thoroughly than the pilot studies already performed.Summary
Ischaemic preconditioning is a physiological mechanism to
protect against ischaemiaereperfusion injury. Mediated by
adenosine, cycles of ischaemia and reperfusion preserve
intracellular ATP levels, prevent lactate build up, and delay
cell death. Once it was discovered that the ischaemia
required to drive this protection in cardiac myocytes could
be performed in other organs, including skeletal muscle, the
concept of remote ischaemic preconditioning was born.
Published clinical trials are currently essentially pilot studies
which broadly show reduction in various biomarkers of or-
gan injury but were not large enough to detect true clinical
outcomes. Meta-analysis of these trials is therefore statis-
tically ﬂawed, but still abundantly popular in the literature.
Importantly, RIPC is cheap, safe, easy to perform, and
scientiﬁcally sound on a physiological level. Larger trials that
will answer the question as to whether this will translate
into clinical beneﬁt are recruiting. The results from the ﬁrst
of these, however, showed no beneﬁt to RIPC.FUNDING
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